Status Epileptikus
Özet
Status epileptikus, çocukluk çağında acil müdahale gerektiren, yüksek morbidite ve mortalite riski taşıyan en önemli nörolojik tablolardan biridir. Tanı, klinik gözlem ve EEG ile hızlıca konulmalı, eş zamanlı olarak havayolu güvenliği ve metabolik dengenin sağlanmasıyla tedaviye derhal başlanmalıdır. Altta yatan etiyolojik nedenlerin belirlenmesi ve yaşa özgü faktörlerin dikkate alınması, doğru yönetim stratejisi için kritik öneme sahiptir. Tedavi protokollerinde benzodiazepinler ilk basamakta yer alırken, dirençli vakalarda ileri basamak farmakolojik seçenekler ve yoğun bakım desteği hayat kurtarıcıdır.
Status epilepticus is one of the most critical neurological emergencies in childhood, requiring urgent intervention due to its high morbidity and mortality risks. Diagnosis must be established rapidly through clinical observation and EEG, with immediate treatment initiation focusing on airway management and stabilization of metabolic balance. Identifying underlying etiologic factors and considering age-specific variables are crucial for implementing the correct management strategy. While benzodiazepines are the first-line treatment in management protocols, advanced pharmacological options and intensive care support are life-saving in refractory cases.
Referanslar
Zimmern V, Korff C. Status Epilepticus in Children. J Clin Neurophysiol. 2020 Sep;37(5):429-433.
Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticusdreport of the ILAE task force on classification of status epilepticus. Epilepsia 2015;56:1515–1523.
Pisani F, Pavlidis E. What is new: talk about status epilepticus in the neonatal period. Eur J Paediatric Neurol 2018;22:757–762.
Canpolat M, Kumandaş S. Management of Status Epilepticus in Children. Turkiye Klinikleri J Pediatr Sci. 2018;14(1):58-81.
Chin RF, Neville BG, Peckham C, Bedford H, Wade A, Scott RC; NLSTEPSS Collaborative Group. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet 2006;368:222–229.
Kravljanac R, Djuric M, Jankovic B, Pekmezovic T. Etiology, clinical course and response to the treatment of status epilepticus in children: a 16-year single-center experience based on 602 episodes of status epilepticus. Eur J Paediatr Neurol 2015;19:584–590.
Schubert-Bast S, Z€ollner JP, Ansorge S, et al. Burden and epidemiology of status epilepticus in infants, children, and adolescents: a population-based study on German health insurance data. Epilepsia 2019;60:911–920.
Logroscino G, Hesdorffer DC, Cascino GD, Annegers JF, Bagiella E, Hauser WA. Long-term mortality after a first episode of status epilepticus. Neurology 2002;58:537–541.
Raspall-Chaure M, Chin RFM, Neville BG, Bedford H, Scott RC. The epidemiology of convulsive status epilepticus in children: a critical review. Epilepsia 2007;48:1652–1663.
Chin RFM. The outcomes of childhood convulsive status epilepticus. Epilepsy Behav. 2019 Dec;101(Pt B):106286.
Watemberg N, Segal G. A Suggested Approach to the Etiologic Evaluation of Status Epilepticus in Children: What to Seek After the Usual Causes Have Been Ruled Out. J Child Neurol. 2010 Feb;25(2):203-11.
Riviello JJ, Ashwal S, Hirtz D, et al. Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review) report of the quality standards subcommittee of the American academy of neurology and the practice committee of the child neurology society. Neurology 2006;67:1542–1550.
Epstein LG, Shinnar S, Hesdorffer DC, et al. Human herpesvirus 6 and 7 in febrile status epilepticus: the FEBSTAT study. Epilepsia 2012;53:1481–1488.
Thompson KW, Suchomelova L, Wasterlain CG. Treatment of early life status epilepticus: what can we learn from animal models? Epilepsia Open 2018;3:169–179.
Kumar SS, Bacci A, Kharazia V, Huguenard JR. A developmental switch of AMPA receptor subunits in neocortical pyramidal neurons. J Neurosci 2002;22:3005–3015.
Rajasekaran K, Zanelli SA, Goodkin HP. Lessons from the laboratory: the pathophysiology, and consequences of status epilepticus. Semin Pediatr Neurol 2010;17:136–143.
Naylor DE, Wasterlain CG. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 2005;25:7724–7733.
Terunuma M, Xu J, Vithlani M, et al. Deficits in phosphorylation of GABAA receptors by intimately associated protein kinase C activity underlie compromised synaptic inhibition during status epilepticus. J Neurosci 2008;28:376–384.
Goodkin HP, Joshi S, Mtchedlishvili Z, Brar J, Kapur J. Subunit-specific trafficking of GABAA receptors during status epilepticus. J Neurosci 2008;28:2527–2538.
Ben-Ari Y. Excitatory actions of GABA during development: the nature of the nurture. Nat Rev Neurosci 2002;3:728–739
Nakajima K, Hirai S, Morio T, Okado H. Benzodiazepines induce sequelae in immature mice with inflammation-induced status epilepticus. Epilepsy Behav 2015;52:180–186.
Torolira D, Suchomelova L, Wasterlain CG, Niquet J. Phenobarbital and midazolam increase neonatal seizure-associated neuronal injury. Ann Neurol 2017;82:115–120.
Mikati MA, Holmes GL, Chronopoulos A, et al. Phenobarbital modifies seizure-related brain injury in the developing brain. Ann Neurol 1994;36:425–433.
Turski CA, Ikonomidou C. Neuropathological sequelae of developmental exposure to antiepileptic and anesthetic drugs. Front Neurol 2012;3:120.
Terrone G, Frigerio F, Balosso S, Ravizza T, Vezzani A. Inflammation and reactive oxygen species in status epilepticus: biomarkers and implications for therapy. Epilepsy Behav 2019. [Epub ahead of print].
Dhote F, Peinnequin A, Carpentier P, et al. Prolonged inflammatory gene response following soman-induced seizures in mice. Toxicology 2007;238:166–176.
Lugrin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. The role of oxidative stress during inflammatory processes. Biol Chem 2014;395:203–230.
Fukuda M, Yamauchi H, Yamamoto H, et al. The evaluation of oxidative DNA damage in children with brain damage using 8- hydroxydeoxyguanosine levels. Brain Dev 2008;30:131–136.
Abend NS, Loddenkemper T. Pediatric status epilepticus management. Curr Opin Pediatr 2014;26(6):668- 74.
Abend NS, Bearden D, Helbig I, McGuire J, Narula S, Panzer JA, et al. Status epilepticus and refractory status epilepticus management. Semin Pediatr Neurol 2014;21(4):263-74. 20.
Grover EH, Nazzal Y, Hirsch LJ. Treatment of Convulsive Status Epilepticus. Curr Treat Options Neurol 2016;18(3):11.
Verrotti A, Ambrosi M, Pavone P, Striano P. Pediatric status epilepticus: improved management with new drug therapies? ExpertOpin Pharmacother 2017;18(8): 789-98.
Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the american epilepsy society. Epilepsy Curr 2016;16(1):48-61.
Betjemann JP. Current trends in treatment of status epilepticus and refractory status epilepticus. Semin Neurol 2015;35(6):621-8
Smith DM, McGinnis EL, Walleigh DJ, Abend NS.Management of Status Epilepticus in Children. J Clin Med 2016;5(4): E47.
Fatema K, Rahman MM, Akhter S, Akter N, Begum S. Non-convulsive Status Epilepticus in Children: Clinical Profile, EEG Characteristics and Treatment. Mymensingh Med J. 2018 Jan;27(1):185-192.
Sutter R, Kaplan PW. Electroencephalographic criteria for nonconvulsive status epilepticus: synopsis and comprehensive survey. Epilepsia. 2012 Aug;53 Suppl 3:1-51.
McKenzie KC, Hahn CD, Friedman JN. Emergency management of the paediatric patient with convulsive status epilepticus. Paediatr Child Health. 2021 Jan 21;26(1):50-66.
Seinfeld S, Leszczyszyn DJ, Pellock JM. Status Epilepticus and Acute Seizure. Pellock JM, Nordli DR, Sankar R, Wheless JW. (Eds) Petiatric Epilepsy. Fourth Edition, New York: Demos Medical Publishing; 2017. p. 567-83.
Fernandez IS, Abend NS, Loddenkemper T. Status Epilepticus. Swaiman KF, Aswal S, Ferriero DM, Schor NF, Finkel RS, Gropman Al, Pearl Pl, Shevell MI (Eds). Swaiman’s Pediatric Neurology. Principles and Practice. (6th Ed). Elsevier Saunders, UK/USA 2017, p. 543-51.
Raj D, Gulati S, Lodha R. Status epilepticus. Indian J Pediatr 2011;78:219-26.
Khoujah D, Abraham MK. Status Epilepticus: What's New? Emerg Med Clin North Am 2016; 34(4):759-76.
Fung EL, Fung BB; Subcommittee on the Consensus Statement of the Hong Kong Epilepsy Society. Review and update of the Hong Kong Epilepsy Guideline on status epilepticus. Hong Kong Med J. 2017 Feb;23(1):67-73.
Chin RF, Neville BG, Scott RC. Meningitis is a common cause of convulsive status epilepticus with fever. Arch Dis Child 2005;90:66–69. [Class III]
Lacroix J, Deal C, Gauthier M, Rousseau E, Farrell CA. Admissions to a pediatric intensive care unit for status epilepticus: a 10-year experience. Crit Care Med 1994;22:827–32.
Tabarki B, Yacoub M, Selmi H, Oubich F, Barasaoui S, Essoussi AS. Infantile status epilepticus in Tunisia: clinical, etiological and prognostic aspects. Seizure 2001;10:365–369.
Dunn DW. Status epilepticus in children: etiology, clinical features, and outcome. J Child Neurol 1988;3:167–173.
Hirtz D, Ashwal S, Berg A, et al. Practice parameter: Evaluating a first non-febrile seizure in children Neurology 2000;55:616–623.
Privitera MD, Strawsurg RH. Electroencephalographic monitoring in the emergency department. Emerg Med Clin North Am 1994;12:1089–1101.
Greenberg MK, Barsan WG, Starkman S. Practice parameter: neuroimaging on the emergency patient presenting with seizure-summary statement. Neurology 1996;47:26–32.
Kramer RE, Luders H, Lesser RP, et al. Transient focal abnormalities of neuroimaging studies during focal status epilepticus. Epilepsia 1987; 28:528–532.
Lansberg MG, O’Brien MW, Norbash AM, Moseley ME, Morrell M, Albers GW. MRI abnormalities associated with partial status epilepticus. Neurology 1999;52:1021–1027.
Kim J, Chung JI, Yoon PH, et al. Transient MR signal changes in patients with generalized tonic clonic seizure or status epilepticus: periictal diffusion-weighted imaging. AJNR Am J Neuroradiol 2001;22: 1149–1160.
Maytal J, Novak G, Ascher C, Bienkowski R. Status epilepticus in children with epilepsy: the role of antiepileptic drug levels in prevention. Pediatrics 1996;98:1119–1121.
Acer H, Canpolat M, Kumandaş S. Status epileptikus tedavisinde güncel gelişmeler. Kumandaş S, Canpolat M, editörler. Çocukluk Çağı Epilepsileri. 1. Baskı. Ankara: Türkiye Klinikleri; 2020. p.179-84.
Lawton B, Davis T, Goldstein H, Tagg A. An update in the initial management of paediatric status epilepticus. Curr Opin Pediatr. 2018 Jun;30(3):359-363.
Abend NS, Loddenkemper T. Pediatric status epilepticus management. Curr Opin Pediatr. 2014;26:668-74.
Zhao ZY, Wen B, Yang ZB, Feng K, Fan JC. A comparison of midazolam, lorazepam, and diazepam for the treatment of status epilepticus in children: a network meta-analysis. J Child Neurol 2016;31:1093–1107.
Brigo F, Nardone R, Tezzon F, Trinka E. Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: a systematic review with meta-analysis. Epilepsy Behav 2015;49:325–336.
Momen AA, Azizi Malamiri R, Nikkhah A, et al. Efficacy and safety of intramuscular midazolam versus rectal diazepam in controlling status epilepticus in children. Eur J Paediatr Neurol 2015;19:149–154.
Cohen NT, Chamberlain JM, Gaillard WD. Timing and selection of first antiseizure medication in patients with pediatric status epilepticus. Epilepsy Res 2019;149:21–25.
Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, et al; NETT Investigators. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366:591-600.
Sreenath TG, Gupta P, Sharma KK, Krishnamurthy S. Lorazepam versus diazepamphenytoin combination in the treatment of convulsive status epilepticus in children: A randomized controlled trial. Eur J Paediatr Neurol. 2010;14:162-8.
.Malu CK, Kahamba DM, Walker TD, Mukampunga C, Musalu EM, Kokolomani J, et al. Efficacy of sublingual lorazepam versus intrarectal diazepam for prolonged convulsions in Sub-Saharan Africa. J Child Neurol. 2013;29:895-902.
Talukdar B, Chakrabarty B. Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: A randomized controlled trial. Brain Dev. 2009;31:744-9.
Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the American epilepsy society. Epilepsy Curr. 2016;16:48-51.
Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3-23.
Bartha AI, Shen J, Katz KH, et al. Neonatal seizures: multicenter variability in current treatment practices. Pediatr Neurol 2007;37:85–90.
Hellstr€om-Westas L, Boylan G, Agren J. Systematic review of neonatal ˚ seizure management strategies provides guidance on anti-epileptic treatment. Acta Paediatr Int J Paediatrics 2015;104:123–129.
Painter MJ, Scher MS, Stein AD, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med 1999;341:485.
Dalziel SR, Borland ML, Furyk J, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. Lancet 2019;393:2135–2145.
Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the American epilepsy society. Epilepsy Curr. 2016;16:48- 61.
Lewena S, Pennington V, Acworth J, Thornton S, Ngo P, McIntyre S, et al. Emergency management of pediatric convulsive status epilepticus: A multicenter study of 542 patients. Pediatr Emerg Care. 2009;25:83- 7.
Yasiry, Z.; Shorvon, S.D. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: A meta-analysis of published studies. Seizure. 2014;23:167-74.
Lyttle MD, Rainford NEA, Gamble C, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet 2019;393:2125–2134.
Yasiry, Z.; Shorvon, S.D. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: A meta-analysis of published studies. Seizure. 2014;23:167-74.
Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5:553-64.
Arkilo D, Gustafson M, Ritter FJ. Clinical experience of intravenous lacosamide in infants and young children. Eur J Paediatr Neurol. 2016;20:212-7.
Grosso S, Zamponi N, Bartocci A, et al. Lacosamide in children with refractory status epilepticus. A multicenter Italian experience. Eur J Paediatr Neurol. 2014;18:604-8.
Bauer S, Willems LM, Paule E, Petschow C, Zöllner JP, Rosenow F, Strzelczyk A. The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience. Ther Adv Neurol Disord. 2017 Feb;10(2):103-126.
Hofler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia. 2013;54:393-404.
Strzelczyk A, Zöllner JP, Willems LM, Jost J, Paule E, Schubert-Bast S, Rosenow F, Bauer S. Lacosamide in status epilepticus: Systematic review of current evidence. Epilepsia. 2017 Jun;58(6):933-950.
Ortiz de la Rosa JS, Ladino LD, Rodríguez PJ, Rueda MC, Polanía JP, Castañeda AC. Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review. Seizure. 2018 Mar;56:34-40.
Eriksson K, Metsaranta P, Huhtala H, Auvinen A, Kuusela AL, Koivikko M. Treatment delay and the risk of prolonged status epilepticus. Neurology. 2005;65:1316-8.
Eriksson KJ, Koivikko MJ. Status epilepticus in children: Aetiology, treatment, and outcome. Dev Med Child Neurol. 1997;39:652-8.
Lowenstein DH. Status epilepticus: an overview of the clinical problem. Epilepsia. 1999;40(Suppl 1):S3-S8.
Tasker RC, Goodkin HP, Sánchez Fernández I, et al. Refractory status epilepticus in children: intention to treat with continuous infusions of midazolam and Pentobarbitalp. Pediatr Crit Care Med 2016;17:968–975.
Van Gestel JPJ, Blussé van Oud-Alblas HJ, Malingré M, Ververs FF, Braun KP, van Nieuwenhuizen O. Propofol and thiopental for refractory status epilepticus in children. Neurology 2005;65:591–592.
Bellante F, Legros B, Depondt C, Créteur J, Taccone FS, Gaspard N. Midazolam and thiopental for the treatment of refractory status epilepticus: a retrospective comparison of efficacy and safety. J Neurol 2016;263:799–806.
Zeiler FA, Teitelbaum J, Gillman LM, West M. NMDA antagonists for refractory seizures. Neurocrit Care 2014;20:502–513.
Rosati A, L’Erario M, De Masi S, et al. Efficacy of ketamine in refractory convulsive status epilepticus in children: a protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01). BMJ Open 2016;6:e011565.
Keros S, Alex B, Antonetty A, et al. Increasing ketamine use for refractory status epilepticus in US pediatric hospitals. J Child Neurol 2017;32:638–646.
Zeiler FA, Zeiler KJ, Teitelbaum J, Gillman LM, West M. Modern inhalational anesthetics for refractory status epilepticus. Can J Neurol Sci 2015;42:106–115.
Fugate JE, Burns JD, Wijdicks EF, Warner DO, Jankowski CJ, Rabinstein AA. Prolonged high-dose isoflurane for refractory status epilepticus: is it safe? Anesth Analg 2010;111:1520–1524.
Mirsattari SM, Sharpe MD, Young GB. Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch Neurol 2004;61:1254–1259.
Kenney-Jung DL, Vezzani A, Kahoud RJ, et al. Febrile infection-related epilepsy syndrome treated with anakinra. Ann Neurol 2016;80:939–945.
Gall CRE, Jumma O, Mohanraj R. Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy. Seizure 2013;22:217–220.
Almaabdi KH, Alshehri RO, Althubiti AA, et al. Intravenous methylprednisolone for intractable childhood epilepsy. Pediatr Neurol 2014;50:334–336.
Broomall E, Grimason M, Goldstein J, et al. Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann Neurol 2014;76:911–915.
Vaitkevicius H, Husain AM, Rosenthal ES, et al. First-in-man allopregnanolone use in super-refractory status epilepticus. Ann 2017;4:411–414.
Zeiler FA, Teitelbaum J, Gillman LM, West M, Kazina CJ. Lidocaine for status epilepticus in pediatrics. Can J Neurol Sci 2015;42:414–426.
Guilliams K, Rosen M, Buttram S, et al. Hypothermia for pediatric refractory status epilepticus. Epilepsia 2013;54:1586–1594.
Corry JJ, Dhar R, Murphy T, Diringer MN. Hypothermia for refractory status epilepticus. Neurocrit Care 2008;9:189–197.
Legriel S, Schenck M, Chelly J, et al. Hypothermia for neuroprotection in convulsive status epilepticus. N Engl J Med 2016;375:2457–2467.
Zeiler FA, Matuszczak M, Teitelbaum J, Gillman LM, Kazina CJ. Electroconvulsive therapy for refractory status epilepticus: a systematic review. Seizure 2016;35:23–32.
Ahmed J, Metrick M, Gilbert A, et al. Electroconvulsive therapy for super refractory status epilepticus. J ECT 2018;34:e5–e9.
Zeiler FA, Zeiler KJ, Teitelbaum J, Gillman LM, West M. VNS for refractory status epilepticus. Epilepsy Res 2015;112:100–113.
Winston KR, Levisohn P, Miller BR, Freeman J. Vagal nerve stimulation for status epilepticus. Pediatr Neurosurg 2001;34:190–192.
Visser NA, Braun KP, Leijten FS, et al. Magnesium treatment for patients with refractory status epilepticus due to POLG1-mutations. J Neurol 2011;258:218–222.
Zeiler FA, Matuszczak M, Teitelbaum J, Gillman LM, Kazina CJ. Magnesium sulfate for non-eclamptic status epilepticus. Seizure 2015;32:100–108.
Lin JJ, Lin KL, Chan OW, Hsia SH, Wang HS. Intravenous ketogenic diet therapy for treatment of the acute stage of super-refractory status epilepticus in a pediatric patient. Pediatr Neurol 2015;52:442–445.
Kossoff EH, Nabbout R. Use of dietary therapy for status epilepticus. J Child Neurol 2013;28:1049–1051.
Cobo NH, Sankar R, Murata KK, Sewak SL, Kezele MA, Matsumoto JH. The ketogenic diet as broad-spectrum treatment for super-refractory pediatric status epilepticus. J Child Neurol 2015;30:259–266.
Appavu B, Vanatta L, Condie J, Kerrigan JF, Jarrar R. Ketogenic diet treatment for pediatric super-refractory status epilepticus. Seizure 2016;41:62–65.
Trinka E, Kälviäinen R. 25 years of advances in the definition, classification and treatment of status epilepticus. Seizure. 2017;44:65- 73.
Akyildiz BN, Kumandaş S. Treatment of pediatric refractory status epilepticus with topiramate. Childs Nerv. Syst 2011;27(9):1425- 30.
Zeiler FA. Early Use of the NMDA Receptor Antagonist Ketamine in Refractory and Superrefractory Status Epilepticus. Crit Care Res Pract. 2015;2015:831260.
Zeiler FA, Teitelbaum J, Gillman LM, West M. NMDA antagonists for refractory seizures. Neurocrit Care. 2014 Jun;20(3):502-13.
Zeiler FA, Zeiler KJ, Teitelbaum J, Gillman LM, West M, Kazina CJ. Lidocaine for status epilepticus in pediatrics. Can J Neurol Sci. 2015;42:414-26.
Nabbout R, Mazzuca M, Hubert P, et al. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in shool age children (FIRES). Epilepsia. 2010;51: 2033-7.
Kravljanac R, Djuric M, Jankovic B, Pekmezovic T. Etiology, clinical course and response to the treatment of status epilepticus in children: A 16-year single-center experience based on 602 episodes of status epilepticus. Eur J Paediatr Neurol. 2015;19(5):584-90.
Au CC, Branco RG, Tasker RC. Management protocols for status epilepticus in the pediatric emergency room: systematic review article. J Pediatr (Rio J). 2017 Nov-Dec;93 Suppl 1:84-94.
Vasquez A, Farias-Moeller R, Tatum W. Pediatric refractory and super-refractory status epilepticus. Seizure. 2019 May;68:62-71.
